Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01163526,9,29,55,46552
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Lui Hac Minh Professor in the School of Medicine
Clinical Professor, Radiology
Colleen Haas Chair in the School of Medicine
Professor of Radiology (Cardiovascular Imaging)
Professor of Radiology (Interventional Radiology)
Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including
unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the
liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.
3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the study
are eligible for enrollment.
3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of
child-bearing age, must take precautions not to become pregnant.
3.1.5 No life expectancy restrictions.
3.1.6 ECOG and Karnofsky Performance Status will not be employed.
3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate
(GFR) must be > 60)
3.1.8 Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of
hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone
chemotherapy within one year prior to the study are also ineligible for enrollment.
3.2.2 No restrictions regarding use of other investigational agents.
3.2.3 Patients with severe contrast allergy are ineligible.
3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this
3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive will
not be excluded.
procedure: CT perfusion
School of Medicine
300 Pasteur Drive
Stanford, CA 94305